Immunic to Participate in Scientific and Medical Conferences in April

Rhea-AI Summary

Immunic (Nasdaq: IMUX) will participate in scientific and medical conferences in April 2026, presenting preclinical and clinical science on its lead asset vidofludimus calcium (IMU-838).

April 14-16: 8th Annual Neuroimmunology Drug Development Summit in Boston; Dr. Hella Kohlhof will present on April 16 at 12:00 pm ET. April 18-22: American Academy of Neurology Annual Meeting in Chicago; Immunic team available at booth #3830. Presentation will be posted in the company's Events and Presentations web section.

News Market Reaction – IMUX

+8.40%

14 alerts

+8.40% Session close to close

+4.8% Peak Tracked

-6.1% Trough Tracked

$169.60M Market Cap

0.6x Rel. Volume

In the Apr 9 session, IMUX gained 8.40%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.8% during that session. Argus tracked a trough of -6.1% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +8.4% in the session following this news. A strong positive reaction aligns with a p...

Analysis

The stock moved +8.4% in the session following this news. A strong positive reaction aligns with a pattern where Immunic’s updates on its lead asset and strategic positioning have previously coincided with favorable price moves. While this announcement focuses on scientific visibility for vidofludimus calcium at April conferences, investors have other context such as a recent S-3 for 458,152,000 resale shares and a planned reverse split. If enthusiasm extended too far, warrant overhang or broader financing dynamics could later cap or reverse a sharp upside move.

Key Figures

Neuroimmunology Summit dates: April 14–16, 2026 Vidofludimus session date: April 16, 2026 Session time: 12:00 pm ET +2 more

5 metrics

Neuroimmunology Summit dates April 14–16, 2026 8th Annual Neuroimmunology Drug Development Summit in Boston

Vidofludimus session date April 16, 2026 Session date for Nurr1 activator presentation

Session time 12:00 pm ET Timing of vidofludimus calcium presentation

AAN meeting dates April 18–22, 2026 2026 American Academy of Neurology Annual Meeting

AAN booth number Booth #3830 Location of Immunic team at AAN meeting

Historical Context

5 past events · Latest: Apr 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 01	Nasdaq compliance update	Positive	+3.6%	Regained compliance with Nasdaq minimum bid price requirement after 20 days above $1.
Mar 31	Board appointment	Positive	+7.8%	Added veteran biopharma executive Jon Congleton to board, enhancing CNS commercialization expertise.
Mar 10	Patent protection	Positive	+3.2%	European patent granted for vidofludimus dosing regimens, extending protection in Europe into 2038.
Mar 03	Investor conferences	Positive	+0.9%	Participation in March investor conferences with leadership panels and one-on-one meetings.
Feb 26	Earnings and update	Positive	+4.1%	Year-end 2025 results plus financing and development timelines for Phase 3 and NDA plans.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent announcements with generally positive or strategic content have all been followed by positive 24-hour price reactions, with no divergences in the last 5 news events.

Recent Company History

Over recent months, Immunic has reported several supportive developments. On Feb 26, 2026, year-end 2025 results and a corporate update highlighted funding into late 2027 and Phase 3 timelines. Subsequent disclosures covered investor conference participation in March, a key European patent extending vidofludimus calcium protection potentially into 2043, and board strengthening via Jon Congleton’s appointment. Most recently, the company regained compliance with Nasdaq’s $1.00 minimum bid rule. Today’s conference-focused news fits into this pattern of ongoing scientific, corporate, and regulatory positioning.

Key Terms

nuclear receptor-related 1 (nurr1), nurr1 activator, neuroprotective, anti-inflammatory, +3 more

7 terms

nuclear receptor-related 1 (nurr1) medical

"lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838)"

Nuclear receptor-related 1 (Nurr1) is a protein that works inside cell nuclei as a gene-regulating switch, helping develop and maintain dopamine-producing brain cells important for movement and mood. For investors, Nurr1 is notable because it is a drug and biomarker target in neurodegenerative and psychiatric research—progress in laboratory studies, patents or clinical trials aimed at modulating Nurr1 can materially influence biotech valuations and risk profiles, much like a promising new engine design can change the prospects of an automaker.

nurr1 activator medical

"lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium"

A nurr1 activator is a drug or compound designed to boost the activity of the Nurr1 protein, a cellular switch that helps maintain certain brain cells. Think of it as turning up a thermostat to restore normal cell function; for investors, such activators matter because they can form the basis of new therapies that, if clinically proven and approved, may create significant commercial value or trigger sharp changes in a developer’s stock based on trial results and regulatory milestones.

neuroprotective medical

"Vidofludimus Calcium Uniquely Combines Direct Neuroprotective & Anti-inflammatory Properties"

Neuroprotective describes a drug, treatment, or compound that helps protect nerve cells from injury, degeneration, or death and can slow or prevent loss of brain or nervous-system function. For investors, claims of neuroprotective activity matter because they suggest a therapy could address chronic or progressive conditions (like those that worsen over time), potentially creating long-term demand, higher development hurdles, and regulatory scrutiny; think of it as a shield for neurons that could change a product’s market value.

anti-inflammatory medical

"Combines Direct Neuroprotective & Anti-inflammatory Properties for the Treatment of Multiple Sclerosis"

A substance or treatment that reduces swelling, redness, pain, or immune overreaction in the body. Investors care because anti-inflammatory products represent a large and steady part of healthcare spending—new or improved treatments can expand markets, change prescribing patterns, lower complication rates, or affect reimbursement and regulatory review, much like a more efficient tool replacing an older one in a toolbox.

multiple sclerosis medical

"Properties for the Treatment of Multiple Sclerosis"

A chronic neurological disease in which the immune system damages the protective coating (like insulation on electrical wires) around nerves, disrupting signals between the brain and body and causing symptoms such as numbness, weakness, vision problems, fatigue and mobility issues. It matters to investors because the unpredictability and long-term nature of the condition drive ongoing demand for treatments, influence the value of companies developing therapies, affect healthcare costs and shape regulatory and reimbursement decisions.

neuroimmune medical

"Beyond Microglia: Unlocking New Neuroimmune Targets To Drive Innovation In CNS Drug Discovery"

Neuroimmune describes the interactions between the nervous system (brain, nerves) and the immune system, and the biological processes that connect them. For investors, it signals a class of therapies or diagnostics aimed at conditions where those systems cross-talk—think of them as two teams coordinating or miscommunicating; drugs that fix the communication can open new markets or change safety and regulatory risk, so trial results and approvals can materially affect a company’s value.

cns medical

"Unlocking New Neuroimmune Targets To Drive Innovation In CNS Drug Discovery"

CNS stands for the central nervous system, the brain and spinal cord that control thought, movement and bodily functions. For investors, CNS-focused products and research matter because therapies aimed at this “delicate wiring” are scientifically challenging, often carry higher development and regulatory risk, and can take longer to prove safe and effective — but successful treatments also tend to command large markets and premium pricing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, April 9, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following scientific and medical conferences in April:

• April 14-16: 8th Annual Neuroimmunology Drug Development Summit. Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will give a presentation highlighting lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), at this conference in Boston. The presentation will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.
  • Presentation Title: Vidofludimus Calcium Uniquely Combines Direct Neuroprotective & Anti-inflammatory Properties for the Treatment of Multiple Sclerosis
  • Presenting Author: Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic
  • Session Title: Beyond Microglia: Unlocking New Neuroimmune Targets To Drive Innovation In CNS Drug Discovery
  • Session Date: Thursday, April 16, 2026
  • Session Time: 12:00 pm ET
    
    
• April 18-22: 2026 American Academy of Neurology (AAN) Annual Meeting. Members of Immunic's management, medical and preclinical teams will attend this meeting in Chicago. The team will be available throughout the event at booth #3830.

About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). The company's development pipeline also includes earlier-stage programs, including IMU-856 and IMU-381, aimed at building a broader therapeutics platform addressing neurodegenerative, chronic inflammatory, and autoimmune-related diseases. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in scientific and medical conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company's subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com

US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-to-participate-in-scientific-and-medical-conferences-in-april-302736609.html

SOURCE Immunic, Inc.

FAQ

When will Immunic (IMUX) present vidofludimus calcium at the Neuroimmunology Summit?

Immunic will present on Thursday, April 16, 2026 at 12:00 pm ET at the Neuroimmunology Summit. According to Immunic, Dr. Hella Kohlhof will discuss vidofludimus calcium's neuroprotective and anti-inflammatory properties in the session 'Beyond Microglia.'

Where can investors view Immunic (IMUX) presentation materials after the April 16 session?

Presentation materials will be posted in the Events and Presentations section of Immunic's investor site. According to Immunic, the Boston presentation will be available at https://ir.imux.com/events-and-presentations following the session.

Will Immunic (IMUX) attend the American Academy of Neurology 2026 meeting in Chicago?

Yes, Immunic's management and scientific teams will attend AAN April 18–22, 2026 and staff the company booth. According to Immunic, the team will be available throughout the event at booth #3830 for meetings and inquiries.

What topic will Immunic (IMUX) cover about vidofludimus calcium at the April conference?

The presentation focuses on vidofludimus calcium combining direct neuroprotective and anti-inflammatory properties for multiple sclerosis. According to Immunic, the talk highlights preclinical and translational data supporting CNS drug discovery targets.

Who is presenting for Immunic (IMUX) at the Neuroimmunology Drug Development Summit?

Hella Kohlhof, Ph.D., Immunic's chief scientific officer, will present at the summit on April 16, 2026. According to Immunic, Dr. Kohlhof will present the session on unlocking new neuroimmune targets and vidofludimus calcium data.